tiprankstipranks
Advertisement
Advertisement

CH:GALD Stock Latest News

Capitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
RatingsCapitalizing on Emerging Aesthetic Demand: Galderma’s Menopause and GLP‑1 Weight Loss Opportunity Supports Reiterated Buy Rating
3d ago
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
PremiumRatings
Galderma Group AG: Buy Rating on Resilient Demand, Growth Catalysts, and Undervalued Long-Term Cash Generation
5d ago
Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
PremiumRatings
Sustained Growth and Favorable Risk‑Reward in Injectable Aesthetics Underpin Galderma Buy Rating
15d ago
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
PremiumRatings
Galderma: Restylane Contour Label Expansion Strengthens Aesthetics Leadership and Supports Buy Rating
20d ago
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
PremiumRatings
Hold Rating Maintained as Supportive FY26 Guidance Offers Limited Upside Versus High Expectations and Valuation
1M ago
Buy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
PremiumRatingsBuy Rating Backed by Strong Q4 Performance, Upgraded Nemluvio Outlook, and Enhanced 2026 Guidance Upside
1M ago
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
Premium
Ratings
Buy Rating on Galderma: Leading Global Skin‑Health Platform with Diversified Growth and Undervalued Upside
1M ago
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
Premium
Ratings
Galderma Buy Rating Underpinned by Strengthened CFO Leadership and Strategic Growth Prospects
2M ago
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
PremiumRatings
Galderma Group AG: Buy Rating Driven by Underappreciated Nemluvio Peak Sales and Pipeline Upside
2M ago
Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
PremiumRatings
Galderma Group AG: Buy Rating Reaffirmed with 19% Price Target Increase Amid Strong Nemluvio Growth Projections
4M ago
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
PremiumRatings
Strategic Partnership and Stake Increase Drive Positive Outlook for Galderma: Buy Recommendation
4M ago
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
PremiumRatings
Galderma Group AG: Promising Growth Outlook and Strategic Expansion Drive Buy Rating
5M ago
Galderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
PremiumRatingsGalderma Group AG: Promising Growth Potential and Strategic Market Positioning Drive Buy Rating
6M ago
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
Premium
Ratings
Galderma Group AG: Strong Q3 Performance Amid Market Challenges, Hold Rating Reflects Balanced Outlook
6M ago
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
Premium
Ratings
Galderma Group AG: Strong Q3 Performance and Growth Potential Justify Buy Rating
6M ago
Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects
PremiumRatings
Galderma Group AG: Buy Rating Affirmed Amid Tariff Challenges and Growth Prospects
7M ago
Strong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance
PremiumRatings
Strong Buy Rating for Galderma Group AG Driven by Nemluvio’s Market Performance and Medical Relevance
7M ago
Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating
PremiumRatings
Galderma Group AG: Strong First Half Performance and Upgraded Sales Outlook Justify Buy Rating
9M ago
Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast
PremiumRatings
Positive Outlook for Galderma Group AG Driven by Strong Nemluvio Prescription Growth and Upbeat Sales Forecast
9M ago
Strong Growth Prospects for Galderma Group AG Driven by Nemluvio’s Performance
PremiumRatingsStrong Growth Prospects for Galderma Group AG Driven by Nemluvio’s Performance
9M ago
Strong Market Performance and Growth Potential Drive Buy Rating for Galderma Group AG
Premium
Ratings
Strong Market Performance and Growth Potential Drive Buy Rating for Galderma Group AG
10M ago
Strong Future Prospects for Galderma Group AG: Buy Rating Supported by Product Uptake and Market Expansion Opportunities
Premium
Ratings
Strong Future Prospects for Galderma Group AG: Buy Rating Supported by Product Uptake and Market Expansion Opportunities
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >